Cantargia AB · OMXSTO:CANTA
Cantargia AB — Redeye Investor Forum 2021
19 slides from Cantargia AB's conference presentation, Oct 14, 2021
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO October 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value ➢ Potentially more effective treatment against novel target in clinically validated pathway ➢ First in class platform technology against novel target ➢ Well financed to build a broad, diversified pipeline ➢ Right team and clear plan to position
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors Current owners (30 Jun 2021) • Positive clinical interim data and further results during 2021 Swedbank Robur Funds 9.7% VISION OF BECOMING AN IMPORTA
Slide 6: II. Lead Antibody Nadunolimab (CAN04)
II. LEAD ANTIBODY NADUNOLIMAB (CAN04)
Slide 7: IL1RAP is overexpressed in most solid tumors
IL1RAP is overexpressed in most solid tumors % IL1RAP-expressing tumors NSCLC biopsy CANFOUR, IL1RAP staining IL1RAP: DISTINCT OVEREXPRESSION IN TUMORS AND LOW NORMAL TISSUE REACTIVITY NSCLC – non-small cell lung cancer HNSCC – head and neck squamous carcinoma 5
Slide 8: CAN04 broad mechanism uniquely enhance docetaxel antitumor activity
CAN04 broad mechanism uniquely enhance docetaxel antitumor activity ✱ 100 → CAN04 in combination with docetaxel in MC38 syngeneic Tumor growth (%) model → CAN04 increase efficacy of docetaxel 50 → Control antibody blocking IL-1β did not have the same effect → In vitro experiment show docetaxel incre
Slide 9: Combination data in NSCLC show promising efficacy
Combination data in NSCLC show promising efficacy → CAN04 in combination with gem/cis in 1st line chemotherapy → 13* of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (48% vs historical control data 22-28%) → No major side
Slide 10: Strong signal in non-squamous NSCLC
Strong signal in non-squamous NSCLC Non-squamous 50 → CAN04 in combination with gem/cis in 1st line chemotherapy Percent tumor reduction Stable disease * * * * * * * Partial response → 8 of 15 evaluable patients with non-sq non-small cell lung 0 * (RECIST 1.1) Complete response cancer (NSCLC) showed
Slide 11: Positive data in pancreatic cancer
Positive data in pancreatic cancer CAN04 in combination with gem/abraxane in 1st line : • Durable responses observed (median DOR 6.8 mo, 27% response rate) • Important finding of pseudoprogression-like response in 5 (15%) patients predicting long PFS. • Promising PFS (7.8 mo) and OS (12.6 mo, 42 % e
Slide 12: Patients with Pseudoprogression-like response
Patients with Pseudoprogression-like response Subject 1 Subject 2 • All presented PD at 1st CT scan evaluation (8 weeks) • All showed concomitant Ongoing reduction of CA19-9 Subject 3 Subject 4 Subject 5 Ongoing PSEUDOPROGRESSION VERY UNCOMMON IN PANCREATIC CANCER INDICATE IMMUNE RELATED MECHANISM O
Slide 13: CAN04/GN in PDAC safety summary and benchmark
CAN04/GN in PDAC safety summary and benchmark Gem/Abraxane CANFOUR FOLFIRINOX Grade 3 or higher AEs (von Hoff) CAN04/GN (Conroy 2011) The beneficial effect in N=421 N=36 N=171 fatigue and chemotherapy- Neutropenia 38% 67% 46% induced neuropathy2 (nab- paclitaxel or oxaliplatin) Febrile neut
Slide 14: III. Untapped Possibilities in Autoimmune Diseases
III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 15: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation) → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease
Slide 16: IV. Milestones and Summary
IV. MILESTONES AND SUMMARY
Slide 17: Market cap change over time
Market cap change over time 2020-2021 what happened? Increase triggered by: • Our clinical data • Speculations around canakinumab • Financing of Flame • Fantastic market climate Decrease triggered by • Canakinumab data • Poor market, sector rotation STRICTLY CONFIDENTIAL
Slide 18: Cantargia reached several milestones and have several value inflection points
Cantargia reached several milestones and have several value inflection points in near future Newsflow over next 6-9 months Nadunolimab (CAN04) → New results PDAC, NSCLC and Keytruda combination → Upcoming trials PDAC and NSCLC → New preclinical and translational results → New clinical trials (FPI) •
Slide 19: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive interim data set and further clinical milestones during 2021 VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS • Combinatio